| Level I | Good quality evidence |
Systematic review of RCTs with consistent findings High quality individual RCT |
| Level II |
Limited quality patient orientated evidence |
Systematic review of lower quality studies or studies with inconsistent findings Low quality clinical trial Cohort studies Case-control studies |
| Level III | Other |
Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |
[7] Carbamazepine, oral (children): National Department of Health, Essential Drugs Programme: Paediatric Hospital Level STGs and EML, 2017. http://www.health.gov.za/
Carbamazepine, oral (children): Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, Mattson R, French JA, Perucca E, Tomson T; ILAE Subcommission on AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013 Mar;54(3):551-63. http://www.ncbi.nlm.nih.gov/pubmed/23350722
Carbamazepine, oral (children): Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database Syst Rev. 2000;(3):CD001030. http://www.ncbi.nlm.nih.gov/pubmed/10908558
Carbamazepine, oral (children): British National Formulary for children 2016-2017. (2016). 1st ed. London: BMJ Group, Pharmaceutical Press and RCPCH Publications Ltd.